# The Effect of Cucumaria frondosa Tentacles Hydrolysates on Dextran Sulfate Sodium-Induced Colitis: Integrated Metagenomics and Metabolomics Analysis

**Authors:** Senyu Zhang, Qiuting Wang, Shunmin Gong, Mingbo Li, Yu Zhang, Leilei Sun, Liqin Sun

PMC · DOI: 10.3390/foods14203483 · 2025-10-13

## TL;DR

This study shows that Cucumaria frondosa tentacles hydrolysates reduce colitis symptoms in mice by modulating gut bacteria and inflammation.

## Contribution

The study introduces a novel nutraceutical candidate for colitis treatment through integrated multi-omics analysis.

## Key findings

- CFTHs reduced colonic inflammation and pro-inflammatory cytokines in a DSS-induced colitis model.
- Metagenomic analysis showed increased Bacteroidetes and reduced Proteobacteria in CFTHs-treated mice.
- Metabolomic profiling identified anti-inflammatory metabolites linked to CFTHs' therapeutic effects.

## Abstract

Inflammatory bowel disease continues to pose substantial therapeutic challenges in modern gastroenterology. This study systematically evaluated the anti-colitis efficacy of Cucumaria frondosa tentacles hydrolysates (CFTHs) using a dextran sulfate sodium (DSS)-induced murine colitis model. Characterized by enhanced stability and solubility with molecular weights below 1000 Da, administration of CFTHs demonstrated a significant mitigation in colitis pathology. Therapeutic outcomes included an improved splenic index, attenuated colonic mucosal damage, and substantial decreases in serum pro-inflammatory cytokines. Relative to the DSS group, the MPO value in the CFTHs-H group decreased by 27.6%, and the IL-6 value exhibited a reduction of 33%. Metagenomic profiling revealed that CFTHs mediated gut microbiota modulation, particularly the enrichment of beneficial Bacteroidetes and suppression of pro-inflammatory Proteobacteria. Metabolomic analysis identified elevated colonic concentrations of anti-inflammatory metabolites such as gamma-linolenic acid and prostaglandin I2, suggesting a microbiome–metabolome crosstalk in the therapeutic mechanism. These multi-omics findings in a murine model suggest that CFTHs may represent a promising candidate for future studies as a nutraceutical intervention for inflammatory bowel disorder. This intervention may operate through mechanisms that include simultaneous immunomodulation, microbiota restoration, and metabolic reprogramming.

## Linked entities

- **Chemicals:** gamma-linolenic acid (PubChem CID 5280933), prostaglandin I2 (PubChem CID 5282411)
- **Diseases:** colitis (MONDO:0005292), inflammatory bowel disease (MONDO:0005265)
- **Species:** Cucumaria frondosa (taxon 36326)

## Full-text entities

- **Genes:** Mpo (myeloperoxidase) [NCBI Gene 17523] {aka mKIAA4033}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}
- **Diseases:** inflammatory (MESH:D007249), Colitis (MESH:D003092), colonic mucosal damage (MESH:D003108), Inflammatory bowel disease (MESH:D015212)
- **Chemicals:** DSS (MESH:D016264), gamma-linolenic acid (MESH:D017965), CFTHs (-), prostaglandin I2 (MESH:D011464)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12562622/full.md

---
Source: https://tomesphere.com/paper/PMC12562622